Summary of the 2025 Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Securities code: 603456 Securities abbreviation: Jiuzhou Pharmaceutical Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
2025 Environmental, Social and Corporate Governance Report Summary
1/6
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Section 1 Important Tips
This summary comes from the full text of the company's "Environmental, Social and Corporate Governance Report". In order to fully understand the relevant impacts, risks and opportunities of the company's environmental, social and corporate governance issues, as well as the company's sustainable development strategy and other related matters, investors should go to the www.sse.com.cn website to carefully read the full text of the company's "Environmental, Social and Corporate Governance Report".
This Environmental, Social and Corporate Governance Report was reviewed and approved by the company’s board of directors.
British Standard Management System Certification (Beijing) Co., Ltd. issued an independent verification opinion statement for the full text of the Environmental, Social and Corporate Governance Report.
2/6
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Section 2 Reporting Basic Situation
- Basic information
Stock code 603456
Company abbreviation: Jiuzhou Pharmaceutical
Company Name Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Report scope Consolidated report scope
Time range January 1, 2025 to December 31, 2025
This report is based on the "Shanghai Stock Exchange Listing" issued by the Shanghai Stock Exchange.
Company Self-Regulation Guidelines No. 14 - Sustainability Report (Trial)" is prepared based on the preparation process. The preparation process complies with the "Sustainability Reporting Standards" (GRIStandards) of the Global Reporting Initiative Global Sustainability Standards Board (GSSB).
2021), and refer to and respond to the United Nations Sustainable Development Goals (UNSDGs)
- Sustainable development governance system
(1) Whether there is a governance body responsible for managing and supervising the impacts, risks and opportunities related to sustainable development: √ Yes, the name of this governance body is the Strategic Decision-making Committee of the Board of Directors. □No
(2) Whether an internal reporting mechanism for sustainable development information has been established: √Yes, the reporting method and frequency are environmental, social and
The corporate governance report is submitted to the board of directors for review once a year. □No
(3) Whether a sustainable development supervision mechanism has been established, such as internal control system, supervision procedures, supervision measures and assessment status, etc.: √ Yes, the relevant systems or measures are based on the Shanghai Stock Exchange's "Self-discipline Supervision Guidelines for Listed Companies No. 14 - Sustainability Reporting (Trial)" and based on ESG risk and opportunity management, the company formulated the "Jiuzhou Pharmaceutical ESG Risk and Opportunity Management Guidelines", which stipulates the company's governance structure, risk and opportunity identification process in ESG risk and opportunity management, and ESG Risk and opportunity management is integrated into the business process; the company held the third meeting of the strategic decision-making committee of the eighth board of directors, which reviewed and approved the "Proposal on Formulating the Terms of Reference of Jiuzhou Pharmaceutical's ESG Executive Committee", the "Proposal on Formulating the "Key ESG Objectives of Jiuzhou Pharmaceutical"" and the "Proposal on Appointing Members of the ESG Executive Committee", which clarified the company's ESG management goals and execution agencies. □No
- Communication with stakeholders
Does the company communicate with and disclose stakeholders through interviews, seminars, questionnaires, etc.: Yes No
☐ ☐Stakeholders Content of Interest Communication Method
Inspections by government and regulatory agencies (national health intellectual property protection leaders and competent authorities)
Health Commission, National Drugs and Water Resources Management, regular work summary and official document exchange supervision bureau, etc.) Innovation and R&D Daily policy implementation
3/6
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
sustainable supply chain management
Climate Change Mitigation and Adaptation Corporation
Regular reports of shareholders’ meetings and official website information governance and information transparency innovation and research
Information disclosure investor hotline, email shareholder and investor distribution service quality improves intellectual property rights
Investor Exchange Conference: The Stock Exchange “Protects Sustainable Supply Chain Management Green”
"Zhenge Interactive" Platform Roadshow Color Chemistry
Sustainable supply chain management climate change
Customer Satisfaction Survey Responses and Differentiation Mitigation and Adaptation Anti-Commercial Bribery
Analysis of customer ESG questionnaire emails and phone calls to customers (pharmaceutical companies) and anti-corruption employee rights and benefits
Daily communication, customer service response, service quality improvement, occupational health and
Customer ComplaintsCustomer VisitsSafety Innovation and R&D
Partners (industry associations, cooperation, innovation and R&D service quality improvement, cooperation agreements, industry activities, such as exhibitions of universities or R&D institutions, suppliers), environmental management green chemistry associations, seminars, etc.
Internal communication platform Employee satisfaction Employee rights and benefits Occupational health
Employees Survey Union Administrative Satisfaction Survey and Safety Employee Training and Development
President’s Reception Day Activities
Employee Rights and Welfare Anti-Commercial Bribery
Bribery and anti-corruption pollutant emissions and public welfare activities media interviews and public communities and the public
Waste treatment occupational health and safety Exchange external announcements and information disclosure
- Dual importance assessment results
The company's ESG report corresponds to the serial number of the Shanghai Stock Exchange's sustainable development report. Importance analysis
Topic Name Guidance Topic Name □ Financial Materiality
1 Innovation and R&D □Importance of Impact Science and Technology Ethics
√Double importance
□Financial importance
2 Improvement of service quality □ Impact importance Product and service safety and quality √ Dual importance
□Financial importance
3 Environmental Management □Impact Importance Environmental Compliance Management
√Double importance
□Financial importance
Pollutant emissions and
4 □Importance of impact Pollutant emissions
waste disposal
√Double importance
4/6
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
The company's ESG report corresponds to the serial number of the Shanghai Stock Exchange's sustainability report. Name of the materiality analysis topic. Name of the guidance topic □Financial materiality.
sustainable supply chain
5 □ Impact Importance Supply Chain Security Management
√Double importance
□Financial importance
Anti-commercial bribery and
6 □ Impact importance Anti-commercial bribery and anti-corruption Anti-corruption
√Double importance
□Financial importance
climate defense mitigation
7 □Importance of impact Response to climate change and adaptation
√Double importance
□Financial importance
Occupational Health and Safety
8 □ Impact importance All employees
√Double importance
□Financial importance
9 Intellectual property protection □ Impact importance Data security and customer privacy protection √ Dual importance
□Financial importance
Data security and privacy
10 □Importance of impact Data security and customer privacy protectionPrivate protection
√Double importance
□Financial importance
Employee Rights and Welfare
11 √ Importance of impact Employee benefits
□Double importance
□Financial importance
12 Green Chemistry √Impact Importance Independently Set Topics □Double Importance
□Financial importance
Employee training and development
13 √Impact and Importance Employee Exhibition
□Double importance
□Financial importance
14 ESG Management √Impact Importance Stakeholder Communication □Double Importance
□Financial importance
Corporate Governance and Trust
15 √Importance of impact, independent setting of topics and information transparency
□Double importance
□Financial importance
community health and public
16 √ Importance of impact Social contribution benefits
□Double importance
5/6
Summary of the Environmental, Social and Corporate Governance Report of Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
The company's ESG report corresponds to the serial number of the Shanghai Stock Exchange's sustainable development report. Importance analysis
Topic Name Guidance Topic Name □ Financial Materiality
17 Contribution to industry development √ Importance of impact Social contribution
□Double importance
√Financial importance
18 Saving use of resources □Importance of impact Energy utilization
□Double importance
□Financial importance
19 Water resources management □ Impact importance Water resources utilization □ Dual importance
□Financial importance
20 Anti-unfair competition □ Importance of impact Anti-unfair competition □ Dual importance
□Financial importance
ecosystem and life
21 □Impact Importance Ecosystem and Biodiversity Conservation Biodiversity
□Double importance
Note:
Regarding the "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 14 - Sustainability Reporting (Trial)"
(hereinafter referred to as the "Guidelines") set the topic of "equal treatment of small and medium-sized enterprises". Based on its actual operating conditions, the company
It has been judged as not applicable in the "preliminary identification of issues" stage of the dual materiality analysis process and is not reflected in the material issues.
matrix, and the reasons are explained in the "Sustainable Supply Chain Management" chapter of this report;
For matters that have been analyzed to have neither financial importance nor impact importance, but are still important to the management of the company
Regarding sexual issues, the company still disclosed information in the corresponding chapters in accordance with the requirements of the guidelines;
Regarding the issue of "science and technology ethics", the company's core business is process development and production, and does not involve drugs that require independent ethical review.
drug discovery and clinical trials, so this topic is not applicable.
6/6